| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
9V
2 T Cells with a Synthetic Phosphoantigen in a Preclinical Nonhuman Primate Model
* Innate Pharma, Marseilles, France;
Institut National de la Santé et de la Recherche Médicale Unité 463, Centre Hospitalier Universitaire Nantes, Quai Moncousu, Nantes, France; and
Institut National de la Santé et de la Recherche Médicale Unité 563, CHU Purpan, Toulouse, France
V
9V
2+ cells represent the major population of T cells in primate blood and react in an MHC-unrestricted fashion to a set of low m.w. nonpeptide phosphoantigens. Two types of structurally related agonists have been discovered so far: the natural phosphoantigens (hydroxydimethyl allyl-pyrophosphate or isopentenyl-pyrophosphate (IPP)) acting directly on V9V2+ TCR and aminobisphosphonates, which block the mevalonate pathway in target cells, leading to accumulation of natural phosphoantigens that in turn activate V9V2+ cells. We demonstrate in the cynomolgus monkey that V9V2 can be manipulated in vivo with bromohydrin pyrophosphate (BrHPP)/Phosphostim, a potent synthetic agonist for which the mechanism of action is similar to natural phosphoantigens. Although of very short half-life, injection of BrHPP leads to strong activation of V9V2, inducing production of a high level of Th1 cytokines. Combination of BrHPP with low-dose rhIL-2 induces specific amplification of effector-memory peripheral V9V2 in blood in a dose-dependant manner. This transient response returns to baseline within 10–15 days. Successive infusions of BrHPP and rhIL-2 induce less vigorous expansions, suggesting a progressive exhaustion of the response. As no toxicity is detected with or without IL-2, this scheme represents a promising immunotherapeutic strategy for induction of systemic Th1 cytokines and massive expansion of T cell subset with antitumor and anti-infectious properties.
This article has been cited by other articles:
|
|
 |
|
  M. S. Braza, A. Caraux, T. Rousset, S. Lafaye de Micheaux, H. Sicard, P. Squiban, V. Costes, B. Klein, and J.-F. Rossi {gamma}{delta} T Lymphocytes Count Is Normal and Expandable in Peripheral Blood of Patients with Follicular Lymphoma, Whereas It Is Decreased in Tumor Lymph Nodes Compared with Inflammatory Lymph Nodes J. Immunol., January 1, 2010; 184(1): 134 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Shao, D. Huang, H. Wei, R. C. Wang, C. Y. Chen, L. Shen, W. Zhang, J. Jin, and Z. W. Chen Expansion, Reexpansion, and Recall-Like Expansion of V{gamma}2V{delta}2 T Cells in Smallpox Vaccination and Monkeypox Virus Infection J. Virol., November 15, 2009; 83(22): 11959 - 11965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Devilder, S. Allain, C. Dousset, M. Bonneville, and E. Scotet Early Triggering of Exclusive IFN-{gamma} Responses of Human V{gamma}9V{delta}2 T Cells by TLR-Activated Myeloid and Plasmacytoid Dendritic Cells J. Immunol., September 15, 2009; 183(6): 3625 - 3633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gertner-Dardenne, C. Bonnafous, C. Bezombes, A.-H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J.-F. Lepage, A. Quillet-Mary, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies Blood, May 14, 2009; 113(20): 4875 - 4884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Huang, C. Y. Chen, Z. Ali, L. Shao, L. Shen, H. A. Lockman, R. E. Barnewall, C. Sabourin, J. Eestep, A. Reichenberg, et al. Antigen-specific V{gamma}2V{delta}2 T effector cells confer homeostatic protection against pneumonic plaque lesions PNAS, May 5, 2009; 106(18): 7553 - 7558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Devaud, E. Bilhere, S. Loizon, V. Pitard, C. Behr, J.-F. Moreau, J. Dechanet-Merville, and M. Capone Antitumor Activity of {gamma}{delta} T Cells Reactive against Cytomegalovirus-Infected Cells in a Mouse Xenograft Tumor Model Cancer Res., May 1, 2009; 69(9): 3971 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Thedrez, C. Harly, A. Morice, S. Salot, M. Bonneville, and E. Scotet IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human V{gamma}9V{delta}2 T Cells for Adoptive Immunotherapy J. Immunol., March 15, 2009; 182(6): 3423 - 3431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gong, L. Shao, Y. Wang, C. Y. Chen, D. Huang, S. Yao, X. Zhan, H. Sicard, R. Wang, and Z. W. Chen Phosphoantigen-activated V{gamma}2V{delta}2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection Blood, January 22, 2009; 113(4): 837 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, K. Luo, and C. D. Pauza TNF-{alpha} Is a Positive Regulatory Factor for Human V{gamma}2V{delta}2 T Cells J. Immunol., November 15, 2008; 181(10): 7131 - 7137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Spencer, G. Abate, A. Blazevic, and D. F. Hoft Only a Subset of Phosphoantigen-Responsive {gamma}9{delta}2 T Cells Mediate Protective Tuberculosis Immunity J. Immunol., October 1, 2008; 181(7): 4471 - 4484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pitard, D. Roumanes, X. Lafarge, L. Couzi, I. Garrigue, M.-E. Lafon, P. Merville, J.-F. Moreau, and J. Dechanet-Merville Long-term expansion of effector/memory V{delta}2- {gamma}{delta} T cells is a specific blood signature of CMV infection Blood, August 15, 2008; 112(4): 1317 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Cummings, C. Cairo, C. Armstrong, C. E. Davis, and C. D. Pauza Impacts of HIV infection on V{gamma}2V{delta}2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS J. Leukoc. Biol., August 1, 2008; 84(2): 371 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, L. Shao, Z. Ali, J. Cai, and Z. W. Chen NSOM/QD-based nanoscale immunofluorescence imaging of antigen-specific T-cell receptor responses during an in vivo clonal V{gamma}2V{delta}2 T-cell expansion Blood, April 15, 2008; 111(8): 4220 - 4232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ali, L. Shao, L. Halliday, A. Reichenberg, M. Hintz, H. Jomaa, and Z. W. Chen Prolonged (E)-4-Hydroxy-3-Methyl-But-2-Enyl Pyrophosphate-Driven Antimicrobial and Cytotoxic Responses of Pulmonary and Systemic V{gamma}2V{delta}2 T Cells in Macaques J. Immunol., December 15, 2007; 179(12): 8287 - 8296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Holderness, L. Jackiw, E. Kimmel, H. Kerns, M. Radke, J. F. Hedges, C. Petrie, P. McCurley, P. M. Glee, A. Palecanda, et al. Select Plant Tannins Induce IL-2R{alpha} Up-Regulation and Augment Cell Division in {gamma}{delta} T Cells J. Immunol., November 15, 2007; 179(10): 6468 - 6478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-J. Puan, C. Jin, H. Wang, G. Sarikonda, A. M. Raker, H. K. Lee, M. I. Samuelson, E. Marker-Hermann, L. Pasa-Tolic, E. Nieves, et al. Preferential recognition of a microbial metabolite by human V{gamma}2V{delta}2 T cells Int. Immunol., May 1, 2007; 19(5): 657 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Thompson and M. J. Rogers Bisphosphonates and {gamma}{delta} T-Cells: New Insights into Old Drugs IBMS BoneKEy, August 1, 2006; 3(8): 5 - 13. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
